Amgen Announces New Data At The American Heart Association Scientific Sessions 2026; New Late-Breaking Findings Show That Repatha Was A Highly Cost-Effective Treatment Option for High-Risk Patients Without A Prior Heart Attack Or Stroke
Amgen Announces New Data At The American Heart Association Scientific Sessions 2026; New Late-Breaking Findings Show That Repatha Was A Highly Cost-Effective Treatment Option for High-Risk Patients Without A Prior Heart Attack Or Stroke
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed